Actinium Pharmaceuticals (ATNM)

Executive Summary

Actinium Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering targeted radiotherapies using the potent alpha-emitting isotope Actinium-225. The company's lead program, Iomab-B, is a Phase 3 targeted conditioning agent designed to improve outcomes for acute myeloid leukemia (AML) patients undergoing bone marrow transplant. Top-line results from the pivotal Phase 3 trial are expected by the end of 2026, which could be a major value inflection point. Additionally, Actinium is advancing ATNM-400, a first-in-class multi-indication therapy for solid tumors, and Actimab-A (lintuzumab Ac-225) for AML. The pipeline also includes Iomab-ACT, a next-generation conditioning agent for cell and gene therapies, and 131I-apamistamab in Phase 2/3 for acute leukemia. With a focus on addressing high unmet needs in hematologic malignancies and solid tumors, Actinium is positioned to capitalize on the growing radiopharmaceutical market. The company's proprietary platform and robust clinical data from ongoing trials support its potential to become a leader in targeted alpha therapy.

Upcoming Catalysts (preview)

• Q4 2026Iomab-B Phase 3 Top-Line Results50% success
• H2 2026ATNM-400 Phase 1/2 Trial Initiation or Initial Data30% success
• TBDStrategic Partnership for Actinium-225 Supply or Co-Development40% success